## 3 Results and Discussion
### In Silico Investigations (Molecular Docking)
All the compounds passed [PERSON]'s rule of five, because none of the compounds exhibited more than one criteria violation. Compounds **C09**, **C10** and **C12** had no violations, but the remaining compounds had only one violation. Most of \begin{table}
\begin{tabular}{c c c c c c c} \hline \hline \multirow{2}{*}{**Compound**} & \multirow{2}{*}{**Chemical Formula**} & \multicolumn{5}{c}{**\(\Delta\)G (kcal/mol)**} \\  & & **NOX** & **5\(-\)LOX** & **MAOB** & **MPO** & **NOS** \\ \hline C01 & C\({}_{18}\)H\({}_{30}\)O\({}_{2}\) & \(-\)5.78 & \(-\)4.79 & \(-\)6.90 & \(-\)5.34 & \(-\)4.99 \\ C02 & C\({}_{18}\)H\({}_{32}\)O\({}_{2}\) & \(-\)4.99 & \(-\)3.81 & \(-\)6.71 & \(-\)7.17 & \(-\)4.24 \\ C03 & C\({}_{18}\)H\({}_{30}\)O\({}_{2}\) & \(-\)5.74 & \(-\)5.81 & \(-\)7.18 & \(-\)6.60 & \(-\)6.89 \\ C04 & C\({}_{20}\)H\({}_{38}\)O\({}_{2}\) & \(-\)6.54 & \(-\)4.58 & \(-\)4.39 & \(-\)7.04 & \(-\)5.85 \\ C05 & C\({}_{17}\)H\({}_{32}\)O\({}_{2}\) & \(-\)4.79 & \(-\)5.96 & \(-\)7.55 & \(-\)5.53 & \(-\)5.78 \\ C06 & C\({}_{18}\)H\({}_{30}\)O\({}_{2}\) & \(-\)4.75 & \(-\)5.87 & \(-\)7.05 & \(-\)6.17 & \(-\)5.30 \\ C07 & C\({}_{16}\)H\({}_{30}\)O\({}_{2}\) & \(-\)6.16 & \(-\)4.84 & \(-\)6.84 & \(-\)5.31 & \(-\)5.40 \\ C08 & C\({}_{16}\)H\({}_{30}\)O\({}_{2}\) & \(-\)5.35 & \(-\)5.10 & \(-\)7.13 & \(-\)6.06 & \(-\)5.77 \\ C09 & C\({}_{12}\)H\({}_{14}\)O\({}_{4}\) & \(-\)5.52 & \(-\)6.30 & \(-\)6.03 & \(-\)6.40 & \(-\)5.77 \\ C10 & C\({}_{17}\)H\({}_{24}\)O\({}_{4}\) & \(-\)7.27 & \(-\)7.50 & \(-\)8.52 & \(-\)8.60 & \(-\)7.98 \\ C11 & C\({}_{24}\)H\({}_{38}\)O\({}_{4}\) & \(-\)6.35 & \(-\)4.74 & \(-\)5.09 & \(-\)4.56 & \(-\)7.21 \\ C12 & C\({}_{16}\)H\({}_{22}\)O\({}_{4}\) & \(-\)5.87 & \(-\)6.91 & \(-\)6.48 & \(-\)6.05 & \(-\)7.50 \\
**Quercetin** & C\({}_{15}\)H\({}_{10}\)O\({}_{7}\) & \(-\)6.87 & \(-\)7.81 & \(-\)8.65 & \(-\)8.38 & \(-\)6.59 \\ \hline \hline \end{tabular}
\end{table} 
Table 6: The chemical formula and binding free energy of the selected ligands. the compounds were highly lipophilic (logP > 5) because they were FAs, except phthalate derivatives (**C09**, **C10**, and **C12**), and quercetin. The other molecular descriptors of all compounds, such as MW, HB donor, and HB acceptor, were in the normal range. However, all the compounds were highly flexible (violating the critical limit of RB), except the compounds **C09**, **C10**, **C12**, and quercetin. Finally, all the extracted compounds obeyed the TPSA normal range, all but the standard compound disobeyed the limit (Table 7). As shown in Table 8, the bioactivity scores were calculated for the phthalate derivatives, FAs, and the standard molecules targeting enzymes, proteases, nuclear receptor, kinases, ion channels, and GPCR. The activities of the compounds are predicted through the calculated bioactivity scores. For instance, scores larger than 0 are probably biologically active, while values \(-\)0.5-0 mean that the compound is moderately active. On the other hand, bioactivity scores below \(-\)0.5 are expected to be inactive [115; 116]. In earlier studies, the correlation between ion channels and diseases related to oxidative stress was predominantly documented in the context of cardiovascular and neurodegenerative pathologies. Several research studies have shown the participation of potassium, sodium, calcium, and chloride channels in the pathogenesis of diseases characterized by significant oxidative stress [117]. The studied FAs **C01**-**C08** showed activity on ion channels modulator, which suggests promising antioxidant capability. According to the results predicted by Molinspiration, all compounds were moderately active on kinase inhibitors, except **C09** and quercetin, which were inactive and active, respectively. In addition, all the compounds and quercetin were active enzyme inhibitors, except **C09**-**C012**, which were moderately active. Compound **C09** was inactive; **C10**-**C12**, **C05**, **C07**, **C08**, and quercetin were moderately active; **C01**-**C04**, and **C06** were active on protease inhibitor.